Literature DB >> 23629014

Diversity of β-lactam resistance mechanisms in cystic fibrosis isolates of Pseudomonas aeruginosa: a French multicentre study.

Catherine Llanes1, Christine Pourcel, Charlotte Richardot, Patrick Plésiat, Gwennaele Fichant, Jean-Didier Cavallo, Audrey Mérens.   

Abstract

OBJECTIVES: To investigate the resistance mechanisms of β-lactam-resistant Pseudomonas aeruginosa isolated from cystic fibrosis (CF) patients in France.
METHODS: Two-hundred-and-four P. aeruginosa CF isolates were collected in 10 French university hospitals in 2007. Their susceptibility to 14 antibiotics and their resistance mechanisms to β-lactams were investigated. Their β-lactamase contents were characterized by isoelectric focusing, PCR and enzymatic assays. Expression levels of efflux pumps and the intrinsic β-lactamase AmpC were quantified by reverse transcription real-time quantitative PCR. Genotyping was performed using multiple-locus variable number of tandem repeats analysis (MLVA). The oprD genes were sequenced and compared with those of reference P. aeruginosa strains. To assess deficient OprD production, western blotting experiments were carried out on outer membrane preparations.
RESULTS: MLVA typing discriminated 131 genotypes and 47 clusters. One-hundred-and-twenty-four isolates (60.8%) displayed a susceptible phenotype to β-lactams according to EUCAST breakpoints. In the 80 remaining isolates, resistance to β-lactams resulted from derepression of intrinsic cephalosporinase AmpC (61.3%) and/or acquisition of secondary β-lactamases (13.8%). Efflux pumps were up-regulated in 88.8% of isolates and porin OprD was lost in 53.8% of isolates due to frameshifting or nonsense mutations in the oprD gene.
CONCLUSIONS: β-Lactam resistance rates are quite high in CF strains of P. aeruginosa isolated in France and not really different from those reported for nosocomial strains. Development of β-lactam resistance is correlated with patient age. It results from intrinsic mechanisms sequentially accumulated by bacteria isolated from patients who have undergone repeated courses of chemotherapy.

Entities:  

Keywords:  AmpC; OprD; antibiotic resistance surveillance; efflux systems; molecular typing

Mesh:

Substances:

Year:  2013        PMID: 23629014     DOI: 10.1093/jac/dkt115

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  25 in total

1.  Amino Acid Substitutions Account for Most MexS Alterations in Clinical nfxC Mutants of Pseudomonas aeruginosa.

Authors:  Charlotte Richardot; Paulo Juarez; Katy Jeannot; Isabelle Patry; Patrick Plésiat; Catherine Llanes
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

Review 2.  The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria.

Authors:  Xian-Zhi Li; Patrick Plésiat; Hiroshi Nikaido
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

3.  In Vitro Activity of Ceftolozane-Tazobactam against Multidrug-Resistant Nonfermenting Gram-Negative Bacilli Isolated from Patients with Cystic Fibrosis.

Authors:  Patrick Grohs; Gary Taieb; Philippe Morand; Iheb Kaibi; Isabelle Podglajen; Marie Lavollay; Jean-Luc Mainardi; Fabrice Compain
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

4.  Constitutive Activation of MexT by Amino Acid Substitutions Results in MexEF-OprN Overproduction in Clinical Isolates of Pseudomonas aeruginosa.

Authors:  Paulo Juarez; Isabelle Broutin; Christophe Bordi; Patrick Plésiat; Catherine Llanes
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

5.  Evaluation of the Accelerate Pheno System: Results from Two Academic Medical Centers.

Authors:  Joseph D Lutgring; Cassiana Bittencourt; Erin McElvania TeKippe; Dominick Cavuoti; Rita Hollaway; Eileen M Burd
Journal:  J Clin Microbiol       Date:  2018-03-26       Impact factor: 5.948

6.  Characterization of a Carbapenem-Hydrolyzing Enzyme, PoxB, in Pseudomonas aeruginosa PAO1.

Authors:  Diansy Zincke; Deepak Balasubramanian; Lynn L Silver; Kalai Mathee
Journal:  Antimicrob Agents Chemother       Date:  2015-11-30       Impact factor: 5.191

Review 7.  Pharmacokinetics and pharmacodynamics of aerosolized antibacterial agents in chronically infected cystic fibrosis patients.

Authors:  Axel Dalhoff
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

Review 8.  Epidemiology, Biology, and Impact of Clonal Pseudomonas aeruginosa Infections in Cystic Fibrosis.

Authors:  Michael D Parkins; Ranjani Somayaji; Valerie J Waters
Journal:  Clin Microbiol Rev       Date:  2018-08-29       Impact factor: 26.132

9.  Impact of FiuA Outer Membrane Receptor Polymorphism on the Resistance of Pseudomonas aeruginosa toward Peptidoglycan Lipid II-Targeting PaeM Pyocins.

Authors:  Libera Latino; Delphine Patin; Dimitri Chérier; Thierry Touzé; Christine Pourcel; Hélène Barreteau; Dominique Mengin-Lecreulx
Journal:  J Bacteriol       Date:  2019-06-10       Impact factor: 3.490

10.  Antimicrobial Susceptibility of Pseudomonas aeruginosa Isolated from Cystic Fibrosis Patients in Northern Europe.

Authors:  Muhammad-Hariri Mustafa; Hussein Chalhoub; Olivier Denis; Ariane Deplano; Anne Vergison; Hector Rodriguez-Villalobos; Michael M Tunney; J Stuart Elborn; Barbara C Kahl; Hamidou Traore; Francis Vanderbist; Paul M Tulkens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.